source
- ReCode Therapeutics appoints Heather Clark as CEO to lead cystic fibrosis and primary ciliary dyskinesia programsReCode Therapeutics announced that Heather Clark will take over as chief executive officer, succeeding founder Shehnaaz Suliman. The transition was presented as a move to keep momentum after the co…
- Viking Therapeutics’ VK2735 shows 17.7% weight loss in Phase 1 and maintains effect with less frequent dosingViking Therapeutics reported Phase 1 results for its injectable GLP-1/GIP dual agonist VK2735, showing an average 17.7% reduction in body weight after 21 weeks of weekly dosing in a placebo-control…